منابع مشابه
Lumiracoxib (Novartis).
Lumiracoxib, an inhibitor of cyclooxygenase 2 (COX-2), is under development by Novartis for the potential treatment of osteoarthritis, rheumatoid arthritis and pain. By late December 2000, phase III trials had been initiated and were ongoing in December 2001.
متن کاملFingolimod. Mitsubishi Pharma/Novartis.
Mitsubishi Pharma Corp and Novartis AG are developing fingolimod, an orally active immunosuppressant affecting lymphocyte re-circulation, for the potential prevention of transplant rejection and the treatment of autoimmune diseases, including multiple sclerosis. Fingolimodis a synthetic sphingosine analog that becomes phosphorylated in vivo and acts as a sphingosine-1-phosphate receptor agonist.
متن کاملSmart health vital signs from the smart home
Dr. Skubic will describe interdisciplinary research in the Center for Eldercare and Rehabilitation Technology at the University of Missouri. Longitudinal research studies with inhome sensing systems have shown that the sensors offer new vital signs for detecting early signs of illness and functional decline. This talk will focus on in-home gait and balance as vital signs for monitoring health s...
متن کاملSmart Signs: Showing the way in Smart Surroundings
This paper presents a context-aware guidance and messaging system for large buildings and surrounding venues. Smart Signs are a new type of electronic doorand way-sign based on wireless sensor networks. Smart Signs present in-situ personalized guidance and messages, are ubiquitous, and easy to understand. They combine the easiness of use of traditional static signs with the flexibility and reac...
متن کاملThe Novartis Foundation
before — a hotbed of gene therapy research. It was a remarkable opportunity. Mulligan was offered one laboratory at the Children's Hospital to work on the basic science of viral vectors, and a second laboratory in a central Harvard building that will manufacture the vectors for use in human trials. Despite all these enticements, Mulligan did not agree to move — and leave a position at the White...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Biotechnology
سال: 2014
ISSN: 1087-0156,1546-1696
DOI: 10.1038/nbt0914-856